Baseline characteristics, initial ART days dispensed, and initial adverse outcomes among patients in the prospective study (n = 402).

OI = opportunistic illness; ART = combination antiretroviral therapy; IQR = inter-quartile range.Percents may not add up to 100% due to rounding.aPatients considered eligible for trimethoprim-sulfamethoxazole included patients being treated for active TB at baseline and patients not being treated for active TB who had a baseline CD4 count 3.bPatients considered eligible for isoniazid preventive therapy included those who did not have known active TB and who did not have a prior history of isoniazid preventive therapy.